Abstract | BACKGROUND: PATIENTS AND METHODS: Eighteen patients with advanced or recurrent gastric cancer were enrolled. The regimen used was intravenous docetaxel, 40 mg/m(2), on day 1 and oral S-1, 80 mg/m(2)/day, on days 1-14 every three weeks. RESULTS: In total 101 cycles were administered. One and 11 patients achieved complete and partial responses, while six and zero patients showed stable and progressive disease, respectively. The median time to progression ( TTP) and median overall survival were 7.0 and 14.3 months, respectively. Neutropenia was the most common grade 3/4 hematological toxicity. Nausea and stomatitis were the most common grade 3 nonhematological toxicities. No treatment-related death was observed. CONCLUSION:
|
Authors | Yasuhiro Tsutani, Masahiro Ohara, Takahisa Suzuki, Kazuhito Minami, Eiji Miyahara, Akira Kameda, Yoshihiro Noso |
Journal | Anticancer research
(Anticancer Res)
Vol. 29
Issue 7
Pg. 2775-9
(Jul 2009)
ISSN: 1791-7530 [Electronic] Greece |
PMID | 19596960
(Publication Type: Journal Article)
|
Chemical References |
- Drug Combinations
- Taxoids
- S 1 (combination)
- Tegafur
- Docetaxel
- Oxonic Acid
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Docetaxel
- Drug Combinations
- Female
- Humans
- Male
- Middle Aged
- Oxonic Acid
(administration & dosage)
- Recurrence
- Stomach Neoplasms
(drug therapy)
- Survival Analysis
- Taxoids
(administration & dosage)
- Tegafur
(administration & dosage)
|